Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
暂无分享,去创建一个
T. Petit | R. Schiappa | P. Marino | A. Bertaut | S. Delaloge | W. Jacot | C. Bellera | D. Pérol | M. Carton | S. Gourgou | T. Filleron | M. Le Deley | M. Robain | C. Lévy | F. Bachelot | Mathias Breton | L. Uwer | C. Courtinard | G. Perrocheau | A. Loeb | S. Pélissier | D. Parent | Laure Vacher | Olivier Guérin
[1] I. Tannock,et al. Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead. , 2022, JAMA oncology.
[2] T. Petit,et al. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database , 2021, Breast.
[3] M. Mouret-Reynier,et al. Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort , 2021, Breast Cancer Research and Treatment.
[4] A. Vincent-Salomon,et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort , 2021, NPJ breast cancer.
[5] E. Eisenhauer,et al. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. , 2021, JAMA oncology.
[6] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[7] R. Rouzier,et al. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program , 2021, Therapeutic advances in medical oncology.
[8] S. Mathoulin-Pélissier,et al. Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME) , 2020, Therapeutic advances in medical oncology.
[9] M. Burkard,et al. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. , 2020, Clinical breast cancer.
[10] B. Kiely,et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.
[11] T. Petit,et al. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study , 2020, AntiCancer Research.
[12] S. Mathoulin-Pélissier,et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. , 2020, European journal of cancer.
[13] H. Rugo,et al. De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry , 2019, The oncologist.
[14] M. Campone,et al. Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program , 2019, International journal of cancer.
[15] T. Petit,et al. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. , 2019, European journal of cancer.
[16] M. Campone,et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort , 2019, British Journal of Cancer.
[17] F. André,et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) , 2019, ESMO Open.
[18] S. Mathoulin-Pélissier,et al. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME) , 2019, BMJ Open.
[19] C. Papadimitriou,et al. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study , 2019, BMC Cancer.
[20] C. Papadimitriou,et al. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study , 2019, BMC Cancer.
[21] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[22] S. Mathoulin-Pélissier,et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. , 2018, European journal of cancer.
[23] Les services de l’Etat à La Réunion. Commission de la transparence , 2018 .
[24] S. Mathoulin-Pélissier,et al. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. , 2017, Critical reviews in oncology/hematology.
[25] S. Khozin,et al. Real-world Data for Clinical Evidence Generation in Oncology. , 2017, Journal of the National Cancer Institute.
[26] Gary H Lyman,et al. Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Asselain,et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] S Michiels,et al. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] S Michiels,et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] C. Beauchemin,et al. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer , 2014, OncoTargets and therapy.
[31] H. Rugo,et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer , 2014, Breast Cancer Research and Treatment.
[32] M. Schemper,et al. Estimating the correlation of bivariate failure times under censoring , 2013, Statistics in medicine.
[33] A. Kesselheim,et al. Reputation and precedent in the bevacizumab decision. , 2011, The New England journal of medicine.
[34] James J. Driscoll,et al. Overall Survival: Still the Gold Standard: Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials , 2009, Cancer journal.
[35] A. Onitilo,et al. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.
[36] J. Cuzick,et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.
[37] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[39] S. Hirschfeld,et al. Oncology drug development: United States Food and Drug Administration perspective. , 2002, Critical reviews in oncology/hematology.
[40] A. Hartz,et al. A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.
[41] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[42] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[43] T. Louis,et al. Inferences on the association parameter in copula models for bivariate survival data. , 1995, Biometrics.
[44] S. Barni,et al. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials , 2013, Medical Oncology.
[45] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[46] G. Molenberghs,et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .